Real-World Findings With Ixazomib, Lenalidomide, and Dexamethasone in Multiple Myeloma
Posted: Tuesday, March 19, 2019
The results of a Hungarian study, conducted by Gergely Varga, PhD, of Semmelweis University in Budapest, and colleagues, focused on efficacy and safety data with the triplet regimen of ixazomib, lenalidomide, and dexamethasone in resistant myeloma. The investigators aimed to gain further insight into the real-world application of this combination therapy in Hungary. Their retrospective study findings were published in Pathology & Oncology Research.
Ixazomib demonstrated high efficacy and safety as the first oral proteasome inhibitor for the treatment of advanced multiple myeloma in the TOURMALINE MM 1 trial, although patient characteristics were limited. In comparison with the Named Patient Program in Hungary, 77 patients were treated at 7 centers, and researchers analyzed their clinical characteristics and survival.
There were significant differences in the levels of pretreatment as well as risk categories. More high-risk patients were included, and no significant differences in outcomes were noted in these patients. Minimal adverse events were reported, with most common adverse events being hematologic toxicities and infections. Three patients did not continue after the first treatment and were therefore excluded from the analysis.
Responses included complete response (12.2 %), very good partial response (10.8 %), partial response (43.2 %), minor response/stable disease (17.6 %), and progressive disease (14.8 %). Progression free survival was 11.4 months, as compared with 20.6 in the TOURMALINE MM1 trial. This discrepancy seemed to highlight the importance of real-world studies in assessing new treatment protocols.
“Our real-world data support the use of ixazomib-lenalidomide-dexamethasone as a highly effective and well tolerated oral treatment protocol for relapsed myeloma,” the researchers concluded.
Disclosure: The study authors reported no conflicts of interest.
